Understand the source comparison
Multi-Target Recovery: KLOW Dosage Comparison
Neurological (CNS) 0.5–0.75mg Subcutaneous or intranasal Once daily or split (AM/PM) Lower doses reflect blood-brain barrier limitations. Higher systemic doses don't increase CNS penetration proportionally Musculoskeletal (localized) 1–2mg Direct tissue inject
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Neurological (CNS)
- 0.5–0.75mg
- Subcutaneous or intranasal
- Once daily or split (AM/PM)
- Lower doses reflect blood-brain barrier limitations. Higher systemic doses don't increase CNS penetration proportionally
- Musculoskeletal (localized)
- 1–2mg
- Direct tissue injection
- Once daily at injury site
- High local concentration saturates receptors at injury sites without systemic distribution. Most efficient route for joint/tendon recovery
- Systemic multi-tissue
- 1–1.5mg
- Subcutaneous
- Split dosing (0.5mg AM, 0.5mg PM)
- Maintains stable plasma levels across diverse tissue types. Split dosing reduces peak-trough variability
- Epithelial/wound healing
- 0.75–1.25mg
- Topical or subcutaneous near site
- Once daily
- Topical application works for surface wounds; deeper tissue damage requires subcutaneous delivery adjacent to injury
- Chronic inflammation
- Once daily or split
- Extended protocols (8+ weeks) may require dose reduction to 0.75–1mg to prevent receptor downregulation